VIDEO: Pembrolizumab plus GVD ‘seems like a win’ in Hodgkin lymphoma
Pembrolizumab plus gemcitabine, vinorelbine and liposomal doxorubicin, or GVD, was an effective second-line therapy in patients with relapsed or refractory classical Hodgkin lymphoma, according to a phase 2 study presented at the ASH Annual Meeting and Exposition.
In a video interview, Ann S. LaCasce, MD, MSc, of Dana-Farber Cancer Institute, told Healio that this was a “very exciting salvage regimen” that yielded high response and complete remission rates, and a favorable toxicity profile.
“The GVD regimen ... is a really nice regimen and combining it with pembrolizumab seems like such a win,” LaCasce said. “I really hope this regimen moves forward because I think it could be a standard salvage regimen.”
Collapse
Moskowitz AJ, et al. Abstract 470. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.